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OBJECTIVE—MBL2 encodes the mannose-binding lectin,
which is a key player in the innate immune system and has
recently been found to play a role in insulin resistance and
development of type 1 diabetes and gestational diabetes mellitus.
To assess the role of MBL2 in diabetes susceptibility, this gene
was analyzed in the Pima Indian population, which has a high
prevalence of type 2 diabetes.
RESEARCH DESIGN AND METHODS—Nineteen tag single
nucleotide polymorphisms (SNPs) were genotyped in a popula-
tion-based sample of 3,501 full-heritage Pima Indians, and se-
lected SNPs were further genotyped in independent samples of
Native American (n  3,723) and Old Order Amish (n  486)
subjects.
RESULTS—Two variants, a promoter SNP (rs11003125) at 550
bp with a risk allele frequency of 0.77 and a Gly54Asp (rs1800450)
with a risk allele frequency of 0.83, were associated with type 2
diabetes in the full-heritage Pima Indians (odds ratio 1.30 per
copy of the G allele for rs1103125, P  0.0007, and 1.30 per copy
of the glycine allele for rs1800450, P  0.002, adjusted for age,
sex, birth year, and family membership). These associations
replicated in an independent Native American sample (1.19, P 
0.04, for rs11003125) and a Caucasian sample, the Old Order
Amish (1.51, P  0.004, for rs1103125 and 2.38, P  0.003, for
rs1800450). Among Pima Indians with normal glucose tolerance,
the diabetes risk allele glycine of Gly54Asp was associated with
a decreased acute insulin response to an intravenous glucose
bolus infusion (P  0.004, adjusted for age, sex, percent body fat,
glucose disposal under physiological insulin stimulation, and
family membership).
CONCLUSIONS—Our data suggest that the functional variants
in MBL2 contribute to type 2 diabetes susceptibility in both
Native Americans and the Old Order Amish. Diabetes 59:
2080–2085, 2010
M
annose-binding lectin (MBL) is a liver-derived
serum lectin involved in the innate immune
defense. Upon binding to speciﬁc carbohy-
drate structures on various microorganisms,
MBL may utilize MBL serine protease (MASP)-2 to activate
the third pathway of complement (lectin pathway) and
thereby opsonophagocytosis (1).
Serum MBL levels have been shown to be strongly
correlated with the presence of variants within the MBL2
gene. Missense polymorphisms at codon 54 (resulting in a
glycine to aspartic acid), codon 57 (resulting in a glycine to
glutamic acid), and codon 52 (resulting in an arginine to
cysteine) impair oligomer formation, leading to reduced
serum levels of functional MBL. In addition, three pro-
moter polymorphisms at position 550 bp G  C (H/l),
221 bp G  C (Y/X) and 4b pC T (P/Q) inﬂuence the
expression of MBL2 (1–3).
Deﬁciency of MBL has been associated with immunode-
ﬁciency, autoimmune disorders such as systemic lupus
erythematosus, and rheumatoid arthritis (4,5). Recent
studies have further implicated MBL deﬁciency in the
development of type 1 diabetes (6), gestational diabetes
mellitus (7), diabetic nephropathy (8), and insulin resis-
tance and obesity (9). Based on the biological role of
MBL2, this gene was investigated as a potential suscepti-
bility gene for type 2 diabetes in Pima Indians.
RESEARCH DESIGN AND METHODS
Subjects in the present study are part of a longitudinal study of the etiology of
type 2 diabetes among the Gila River Indian Community in Arizona, where
most of the residents are Pima Indians or of the closely related Tohono
O’odham tribe. Diabetes status was determined by an oral glucose tolerance
test according to the criteria of the World Health Organization (10). The initial
genetic study was conducted in a population-based sample of full-heritage
Pima Indians (n  3,501), where 1,561 subjects had type 2 diabetes (37% male,
age at the last exam 49  14 years, and BMI 39  8 kg/m
2) and 1,940 subjects
were nondiabetic (46% male, age at the last exam 31  15 years, and BMI 36 
8 kg/m
2). Independent replication was assessed in 3,723 subjects from the
same longitudinal study who were of mixed Native American heritage
(reported heritage, on average, was one-half Pima and three-quarters Native
American). The replication sample had 750 subjects with type 2 diabetes (41%
male, age at the last exam 42  14 years, and BMI 38  9 kg/m
2) and 2,973
nondiabetic subjects (47% male, age at the last exam 24  11 years, and BMI
34  8 kg/m
2). Additional replication was assessed in a case-control sample
from the Old Order Amish (139 diabetic subjects and 347 subjects with normal
glucose tolerance) as previously described (11).
Metabolic quantitative traits. Among the full-heritage Pima Indians, 415
subjects (58% male, age 27  6 years, and BMI 34  8 kg/m
2) had undergone
detailed metabolic testing for risk factors that predict type 2 diabetes. These
individuals were determined to be nondiabetic, and acute insulin response
was only analyzed in subjects who had normal glucose tolerance. Glucose
tolerance was determined by a 75-g oral glucose tolerance test (OGTT) with
measurements of fasting and 30, 60, 120, and 180-min plasma glucose and
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was measured on a separate day from the OGTT. Blood samples were
collected prior to a 25-g glucose intravenous bolus infusion and at 3, 4, 5, 6, 8,
and 10 min after infusion. The acute insulin response was calculated as the
mean increment in plasma insulin concentrations from 3–5 min (13). Insulin
sensitivity was assessed using the hyperinsulinemic-euglycemic clamp tech-
nique as previously described (12,13). Body composition was estimated by
underwater weighing until January 1996 and by dual-energy X-ray absorpti-
ometry (DPX-1; Lunar Radiation) thereafter (14).
SNP identiﬁcation and genotyping. DNA from 24 Pima Indians (12 nondi-
abetic and aged 45 years; 12 diabetic with onset age 25 years) was
sequenced using a Big Dye terminator (Applied Biosystems) on an automated
DNA capillary sequencer (model 3730; Applied Biosystems). Genotyping was
done using the SNPlex genotyping system 48-plex (Applied BioSystems) on an
automated DNA capillary sequencer (model 3730; Applied Biosystems) for the
Native American samples and Taqman genotyping assays (Applied Biosys-
tems) for the Old Order Amish samples.
Statistical analysis. In the Pima study, statistical analyses were performed
using the software of the SAS Institute (Cary, NC). The general association of
genotypes with type 2 diabetes was assessed by logistic regression analysis
and was adjusted for covariates (age, sex, and birth year). The model was ﬁt
with a generalized estimating equation technique to account for correlation
among siblings. Genotype was analyzed as a numeric variable representing the
number (0, 1, 2) of copies of a given allele. The association of quantitative
traits with genotypes was analyzed by linear regression using the generalized
estimating equation procedure to account for correlation among siblings. P
values were adjusted for potential confounding covariates. In the replication
study, which included individuals of mixed ancestry, the individual estimate of
European admixture was also used as a covariate. These estimates were
derived by the method of Hanis et al. (15) from 39 informative markers with
large differences in allele frequency between populations (16). Linkage
disequilibrium (LD) and haplotype blocks were estimated by Haploview
(version 3.32).
For the Amish study, the odds ratio (OR) is derived from a logistic
regression model, while the P value is based on the normal-liability threshold
model implemented in SOLAR to account for relationships among individuals.
CIs (and the approximate SE) are test based (17,18).
RESULTS AND DISCUSSION
Sequencing of the MBL2 gene (all four exons, three introns,
and 2 kb of the upstream region) in 24 Pima Indians
identiﬁed 37 variants. Three were previously known vari-
ents which predicted missense substitutions—rs5030737
(Arg52Cys), rs1800450 (Gly54Asp), and rs1800451 (Gly57Glu)—
commonly referred to as A/D, A/B, and A/C, respectively
(1–2). Three known promoter SNPs, rs11003125,
rs7096206, and rs7095891, previously classiﬁed as 550
G  C (H/l),  221G  C (Y/X), and 4C T (P/Q),
respectively, were also identiﬁed (3). From these 37
SNPs in the MBL2 gene, 12 tag SNPs were selected
based on the tagger algorithm (Haploview 3.32, using R
2
 0.8 to indicate redundancy [supplementary Fig. 1,
available in the online appendix at http://diabetes.
diabetesjournals.org/cgi/content/full/db09-1593/DC1]). To
additionally analyze variation ﬂanking MBL2 (25 kb
ﬂanking each side of the sequenced region, chromosome
10:54170146–54228466), 20 database SNPs that serve as
tag SNPs in the Chinese HapMap (R
2  0.8; minor allele
frequency 0.1) were genotyped in Pima Indians, and it
was determined that seven SNPs could serve as tag SNPs
(deﬁned above) in Pima samples (supplementary Fig. 1).
All 19 tag SNPs (12 in MBL2 and 7 ﬂanking) were
genotyped in the sample of 3,501 full-heritage Pima Indi-
ans for association analysis with type 2 diabetes (Table 1).
The missense SNP rs1800450 (Gly54Asp, designated A/B)
and the promoter SNP rs11003125 (designated H/l) were in
high LD (D0.99; R
2  0.71) and were associated
with type 2 diabetes (P  0.002 and 0.0007, respectively,
adjusted for age, sex, birth year, and family membership;
Table 1). These two tag SNPs captured several additional
SNPs within intron 2 and the region near MBL2.
To determine whether the association with type 2
diabetes in the full-heritage Pima Indians could be
replicated in other Native Americans, rs1800450 and
rs11003125 were further genotyped in a nonoverlapping
sample of 3,723 subjects who were predominately of
mixed Native American heritage. The promoter SNP
rs11003125 reproducibly associated with type 2 diabetes
(P  0.04, adjusted for age, sex, birth year, and heritage)
(Table 1). Combining the initial and replication samples
(n  7,224) provided the strongest evidence for associa-
tion with type 2 diabetes for rs11003125 (P  9.2 	 10
5)
(Table 1). The combined sample also showed a signiﬁcant
association for rs1800450 (P  0.001) (Table 1), but this
signiﬁcant association was largely driven by the initial
full-heritage Pima sample, with only a nonsigniﬁcant asso-
ciation in the same direction (P  0.18) identiﬁed in the
largely mixed-heritage replication group.
To determine whether variants in MBL2 had a signiﬁ-
cant effect on diabetes in non–Native American popula-
tions, rs1800450 and rs11003125 were genotyped in an
Amish sample of 139 diabetic subjects and 347 subjects
with normal glucose tolerance. Consistent with the Native
American samples, rs11003125 was associated with type 2
diabetes in the Amish (OR 1.51; P  0.004, adjusted for
age, sex, and family structure) (Table 2), but the frequency
of risk allele G was lower in the Amish than in Pima
Indians (0.45 vs. 0.77, respectively). The SNP rs1800450
(Gly54Asp) was also associated with type 2 diabetes in
the Amish (OR 2.38, adjusted P  0.003) (Table 2), but the
frequency of risk allele glycine was comparable in the
Amish and Pima Indians (0.87 vs. 0.83). In contrast, these
associations do not appear to replicate in the large Cau-
casian Diabetes Genetics Replication and Meta-analysis
(DIAGRAM) (19). Neither of these SNPs were directly
genotyped in genome-wide association (GWA) studies
from the Diabetes Genetics Initiative (DGI) and the Well-
come Trust Case Control Consortium (WTCCC), which are
two of the three large studies from which the meta-
analysis was derived; however, a proxy, rs1838065, which
we determined to have an R
2  1 with rs11003125 (based
on our genotyping of 90 Caucasians), was not associated
with type 2 diabetes in DIAGRAM (P  0.35, Table 2).
Combining the negative DIAGRAM data together with the
positive Amish and Native American data rendered the
overall combined association nonsigniﬁcant (P  0.17)
(Table 2).
Data across a larger genomic region encompassing
MBL2 could also be obtained from prior GWA studies in
Pima Indians (20), DGI (21), WTCCC (22), and DIAGRAM
(19). For example, a 400 kb region encompassing the
8.3 kb MBL2 (chromosome 10: 54007027–54401287)
yielded 101 SNPs that were previously genotyped in a
GWA study of Pima Indians. Only one GWA study SNP
(rs1838065) was located within MBL2 (intron 2). The
pairwise LD pattern of these 101 SNPs and their associa-
tion with early-onset type 2 diabetes in Pima subjects who
were analyzed in this prior GWA (300 early-onset diabetes
case and 334 control subjects) are shown in supplemen-
tary Fig. 2A and B. GWA study SNP rs1838065, which is in
near-perfect LD with the promoter rs11003125 (R
2  0.99),
was associated with early-onset type 2 diabetes (deﬁned as
diabetes onset 25 years of age) in the GWA study
(adjusted P  0.0006), as were several nearby GWA study
SNPs (adjusted P  0.0007–0.005) (supplementary Fig. 2),
which were in high LD among themselves (R
2  0.66–
0.99) but in low LD with rs1838065 (R
2  0.30–0.37). In
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(tagged by rs920727) had only a borderline association
with type 2 diabetes (deﬁned as diabetes at any age) in the
current larger study of 3,501 full-heritage Pima subjects
(rs920727, P  0.05) (Table 1). GWA study data across this
region in the DGI and WTCCC studies and DIAGRAM are
shown in supplementary Fig. 3. Overall, there were no
consistent associations with type 2 diabetes across the
region in any of these Caucasian studies. When GWA
study results of Pimas were compared with other pop-
ulations in the MBL2 region, rs1838065 was not signiﬁcant
in DIAGRAM. SNPs tagged by rs17587392 in Caucasians
had a borderline signiﬁcance with type 2 diabetes in
DIAGRAM (P  0.05) (supplementary Fig. 3) but was
nearly monomorphic (minor allele frequency 0.001) and
therefore uninformative in full-heritage Pima Indians,
while SNP rs11003132, which had a borderline association
with type 2 diabetes in WTCCC (P  0.05) (supplementary
Fig. 3), was not associated with type 2 diabetes in Pima
Indians (Table 1).
TABLE 1
Associations of MBL2 tag SNPs with type 2 diabetes in Pima Indians
SNP Location
Risk/
non-risk
Full-heritage Pima Indian
(n  3,501)
Replication mixed heritage
(n  3,723) Combined (n  7,224)
AF OR (95% CI) Padditive AF OR (95% CI) Padditive OR (95% CI) Padditive
rs920727 3-ﬂanking T/C 0.90 1.23 (1.01–1.51) 0.05
rs11003107 3-ﬂanking C/T 0.99 1.04 (0.69–1.56) 0.85
rs11003120 3-ﬂanking C/T 0.99 4.05 (0.87–18.5) 0.07
rs10082466 3UTR T/C 0.92 1.12 (0.89–1.40) 0.32
Novel: 3UTR 3UTR A/G 0.08 1.12 (0.90–1.42) 0.32
rs930507 Leu126Leu C/G 0.98 1.27 (0.86–1.88) 0.22
rs10824793 Intron 2 A/G 0.95 1.27 (0.97–1.65) 0.08
rs55902142 Intron 2 A/G 0.01 1.76 (1.00–3.10) 0.05
rs1800451 Gly57Glu
(A/C)
G/A 0.99 1.17 (0.14–9.80) 0.88
rs1800450 Gly54Asp
(A/B)
G/A 0.83 1.30 (1.10–1.53) 0.002 0.83 1.12 (0.94–1.40) 0.18 1.24 (1.09–1.40) 0.001
rs5030737 Arg52Cys
(A/D)
C/T 0.99 1.95 (0.47–8.06) 0.35
rs7095891 Promoter
(P/Q)
C/T* 0.97 1.28 (0.88–1.88) 0.19 0.91 1.05 (0.80–1.39) 0.69 1.13 (0.91–1.41) 0.28
rs7096206 Promoter
(Y/X)
G/C* 0.99 2.20 (0.92–5.21) 0.07
rs11003125 Promoter
(H/l)
G/C* 0.77 1.30 (1.12–1.51) 0.0007 0.68 1.19 (1.01–1.41) 0.04 1.25 (1.12–1.40) 9.2 	 10
5
Novel:
promoter Promoter G/A 0.98 1.20 (0.69–2.08) 0.51
rs11003132 5-ﬂanking C/T 0.99 1.47 (0.79–2.74) 0.22
rs10762885 5-ﬂanking A/G 0.97 1.24 (0.87–1.76) 0.22
rs11003138 5-ﬂanking C/T 0.91 1.14 (0.92–1.40) 0.23
rs10824804 5-ﬂanking A/C 0.88 1.28 (1.05–1.57) 0.02
Nineteen tag SNPs (R
2 0.8) were selected from 57 SNPs that span MBL2 (8.3 kb) and approximately 25 kb ﬂanking each side of the gene.
Allele frequency (AF) is presented as frequency of the risk allele. OR is expressed as per copy of the risk allele (and thus, by deﬁnition, is
1). The risk allele is underlined where the P value is 0.05. *Genotypes were determined according to the reverse strand of the SNP
database sequence. Sequences ﬂanking the two novel SNPs are as follows: novel: promoter, tttcatggatgggtgtgtgc
g/atgcatgcacgtgtctgtgtg;
novel: 3UTR, catgactgcacagtaatttc
g/atctgtttataaacattgtat.
TABLE 2
Association of promoter rs1103125 and rs1800450 (Gly54Asp) with type 2 diabetes in Pima Indian, Amish, and DIAGRAM subjects
rs11003125 rs1800450
OR (95% CI) PP het OR (95% CI) PP het
Native American
Full-heritage Pima Indian 1.30 (1.12–1.51) 0.0007 1.30 (1.10–1.53) 0.002
Replication mixed heritage 1.19 (1.01–1.41) 0.04 1.15 (0.94–1.40) 0.18
Combined 1.25 (1.12–1.40) 9.2 	 10
5 0.45 1.24 (1.09–1.40) 0.001 0.35
Caucasian
Amish 1.51 (1.10–2.08) 0.004 2.38 (1.36–4.17) 0.003
DIAGRAM* 0.97 (0.91–1.03) 0.35
Combined 0.99 (0.93–1.05) 0.66 0.008
Native American and Caucasian
combined 1.04 (0.98–1.10) 0.17 0.0002
A combined test was conducted by the inverse variance method. ORs are per copy of the risk allele identiﬁed in the full-heritage Pima sample.
P is for the null hypothesis that the OR  1. Phet is the P value for the null hypothesis that the ORs are the same for the combined groups.
*DIAGRAM results based on rs1838065, which has an R
2 of 1.0 with rs1103125.
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associations with type 2 diabetes in Native Americans and
a small group of Amish subjects, who are of European
descent but were not associated with diabetes in the large
DIAGRAM, is unexpected. It is possible that the associa-
tion in the Amish is a false positive. Alternatively, both the
Pima Indians and the Old Order Amish represent far more
homogeneous populations compared with the study pop-
ulation of DIAGRAM. It is also possible that susceptibility
genes for common diseases may have larger effects in
these populations compared with others as a result of
segregation of high-penetrance alleles that are rare or
nonexistent in the general population, gene-gene or gene-
environment interactions, or the absence of other suscep-
tibility genes whose effects could mask other genes.
To aid in validating the positive associations with type 2
diabetes, we further investigated whether these variants in
MBL2 were associated with metabolic risk factors that
predict type 2 diabetes among 415 nondiabetic, full-heri-
tage Pima Indians. For both rs11003125 and rs1800450, the
allele associated with higher risk for diabetes (G and
glycine, respectively) was associated with a higher 2-h
plasma glucose concentration (adjusted P  0.0005 and
0.04, respectively) and higher 2-h plasma insulin concen-
tration (adjusted P  0.0008 and 0.003, respectively)
during an oral glucose tolerance test (Table 3). The risk
allele glycine for rs1800450 was additionally associated
with a lower acute insulin response to an intravenous
glucose bolus infusion (adjusted P  0.004) among sub-
jects who had normal glucose tolerance (n  281) (Table
3). However, neither SNP was associated with insulin-
stimulated glucose uptake.
Previous functional studies have shown that serum MBL
levels are greatly inﬂuenced by variants within the
MBL2 gene. Three promoter variants (rs11003125 [H/l],
rs7096206 [Y/X], and rs7095891 [P/Q]) and three missense
variants (rs5030737 [A/D], rs1800450 [A/B], and rs1800451
[A/C]) were previously associated with MBL deﬁciency
(3,23). Several of these variants are in high LD, so a limited
number of haplotypes are present in humans. HYPA
(G-G-C-Gly) haplotype carriers have the highest serum
concentration of MBL, typically from 1,400 to 2,500 g/l,
whereas LYPB (C-G-C-Asp) haplotype carriers have the
lowest serum concentration: 20–400 g/l (3,20). Since
rs7096206 (Y/X) and rs7095891 (P/Q) are very rare in Pima
Indians (minor allele frequency 0.03), these high versus
low serum level haplotypes can essentially be determined
from a two-SNP haplotype of the promoter rs11003125
(H/l) and missense rs1800450 (A/B) in Pima Indians.
Haplotype analysis for rs11003125 and rs1800450 was
performed in the combined sample of 7,224 predominately
Pima Indians. The haplotype G-glycine (HA), carrying both
the G nucleotide (designated H allele) of the promoter
rs11003125 and glycine (designated A allele) of rs1800450,
was associated with increased risk for type 2 diabetes in
Pima Indians (haplotype frequency of G-glycine 0.78 in
diabetic vs. 0.71 in nondiabetic; OR 1.25 [95% CI 1.12–1.33],
P  0.0001, adjusted for age, sex, and birth year [heritage
estimate in the replication group]). Because this haplotype
G-glycine is highly concordant with the G (H) allele of
rs11003125 (R
2  0.99), it is difﬁcult to statistically distin-
guish the single genotypic versus haplotypic effects. When
both SNPs are included in a single model, there is a
signiﬁcant association with rs11003125 (OR 1.29 [95% CI
1.08–1.54]; P  0.005) conditional on the effect at
rs1800450, but there is little association with rs1800450
TABLE 3
Metabolic characteristics of full-heritage nondiabetic subjects grouped by genotypes of promoter rs11003125 or rs1800450 (Gly54Asp)
variants
rs11003125 (G/C) rs1800450 (G/A)
G/G G/C C/C Padditive
G/G
(Gly/Gly)
G/A
(Gly/Asp)
A/A
(Asp/Asp) Padditive
Nondiabetic subjects
n 233 134 16 271 108 16
Percent body fat 32  0.5 33  0.7 34  1.9 0.60 32  0.5 33  0.8 36  1.8 0.86
BMI (kg/m
2) 33  0.5 33  0.6 34  2.2 0.56 33  0.4 33  0.7 37  2.0 0.21
Fasting plasma glucose (mg/dl) 90  0.6 89  0.8 87  2.2 0.09 89  0.5 89  0.8 89  2.5 0.29
60-min plasma glucose (mg/dl) 150  2.1 146  3.0 137  7.3 0.02 149  2.0 145  3.5 146  7.7 0.12
2-h plasma glucose (mg/dl) 125  1.9 122  2.6 106  6.1 0.0005 124  1.8 122  2.9 116  8.0 0.04
Log fasting plasma insulin
(U/ml) 1.55  0.01 1.54  0.01 1.55  0.05 0.31 1.56  0.01 1.52  0.01 1.62  0.04 0.17
Log 2-h plasma insulin (U/ml) 2.22  0.02 2.15  0.02 2.09  0.07 0.0008 2.21  0.02 2.13  0.03 2.17  0.07 0.003
Log glucose disposal rate
under low-dose insulin
clamp (mg  kg EMBS
1 
min
1) 0.54  0.01 0.55  0.01 0.53  0.02 0.34 0.54  0.01 0.56  0.01 0.50  0.02 0.32
Normal glucose tolerant subjects
n 164 99 9 192 80 9
Log acute insulin response
(U/ml) 2.33  0.02 2.35  0.02 2.49  0.07 0.14 2.32  0.04 2.37  0.02 2.52  0.02 0.004
Log 30-min plasma insulin
(U/ml) 2.34  0.01 2.34  0.02 2.41  0.13 0.31 2.34  0.01 2.35  0.02 2.40  0.12 0.27
Data are means  SE unless otherwise indicated. Plasma insulin concentrations (fasting, 2 h, and 30 min), rates of glucose disappearance
during the low-dose insulin stimulation, and the acute insulin response were log transformed before analyses to approximate a normal
distribution. The P value for percent body fat was adjusted for age, sex, and family membership. The P value for the acute insulin response
was adjusted for age, sex, percent body fat, and rate of glucose disappearance during the low-dose insulin stimulation. All remaining P values
(except for age) were adjusted for age, sex, percent body fat, and family membership. EMBS, estimated metabolic body size.
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0.61). It thus appears that the promoter rs11003125 is the
stronger predictor of diabetes, with little additional infor-
mation from rs1800450.
The prevalence of type 2 diabetes was plotted in the
full-heritage Pima Indian (n  3,081) (Fig. 1A) and the
replication Native American (n  3,504) (Fig. 1B) groups
according to the genotypes of rs11003125 and rs1800450.
Ordering the genotypic groups according to their associa-
tion with serum MBL levels showed that subjects homozy-
gous for both G and glycine alleles had a higher prevalence
of diabetes than did subjects homozygous for the C allele
and either homozygous or heterozygous for the aspartic
acid alleles (Ptrend  8.4 	 10
5 in the combined analysis
of 6,585 predominately Pima subjects, adjusted for age,
sex, and birth year, and in the replication group, heritage).
In Caucasians, Eskimos, Africans, South Americans, and
Native Americans, the G-glycine (HA) haplotype is associ-
ated with higher MBL serum level (3,24–26).
The present study demonstrates that an allele for MBL2,
which arises predominately from the promoter SNP
rs11003125 (G allele), predicts a higher serum level of
MBL2 and is associated with increased risk for type 2
diabetes, increased 2-h plasma glucose and 2-h plasma
insulin, and decreased insulin secretion in some popula-
tions. Consistent with our observations, high MBL2 levels
have recently been reported to be associated with high
A1C levels in the Strong Heart Study, a longitudinal study
of cardiovascular disease among Native Americans (26).
SNP rs11003125 is in high LD with other SNPs that map
within intron 2 and a ﬂanking region of MBL2; therefore,
the contribution of other functional SNPs cannot be ruled
out. Nevertheless, both high LD and diabetes association
were restricted to the region in and near MBL2, suggesting
that evidence for association with type 2 diabetes is more
likely derived from MBL2 rather than other genes in the
region.
Although the physiologic mechanisms underlying the
association of MBL2 levels with diabetes are unknown, it
has previously been shown that MBL2 plays a dual role in
modifying inﬂammatory responses (27). Deﬁciency of
MBL has been linked to increased risk of developing type
1 diabetes (6), insulin resistance, and obesity (9) as a
result of a chronic infectious state or low-grade inﬂamma-
tion. MBL2 could also affect metabolic pathways through
stimulating fatty acid oxidation in skeletal muscle (28) or
reducing release of tumor necrosis factor-
, interleukin-1,
and interleukin-6 (29). In contrast, increased MBL levels
could lead to an overly activated complement system,
thereby inducing inﬂammatory damage or interweaving a
complex autoimmune process (30). Consistent with the
latter effect, high MBL levels have been associated with
increased risk for insulin resistance in pregnancy (31) and
late-onset of rheumatoid arthritis (5). However, our study
indicates that MBL2 variants are more likely to inﬂuence
type 2 diabetes via an effect on insulin secretion rather
than on insulin action, suggesting that inﬂammatory dam-
age in pancreatic -cell function may be involved. Addi-
tional studies are needed to investigate the impact of this
gene on speciﬁc type 2 diabetes related–pathways and
disease susceptibility in non–Native American groups.
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